A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Currently hospitalized or under immediate consideration for hospitalization at screening and Day 1
• •Have new onset shortness of breath or increased shortness of breath from pre-COVID-19 (for people with known COPD) at screening and Day 1
• •Hypoxemia (oxygen saturation \<94% in ambient air or oxygen saturation below pre-COVID-19 level for people with known COPD) at Day 1
• •Require supplemental oxygen (new requirement or increase in requirement from pre-COVID-19 condition) at screening and Day 1
• •Have a history of (in the past 3 months) or current active pathological bleeding
• •Have a history of hemorrhagic stroke or intracranial hemorrhage
• •Have a recent severe head trauma within 30 days which includes concussion, skull fracture or hospitalization for head injury
• •Have known intracranial neoplasm, cerebral metastases, arteriovenous malformation or aneurysm
• •Have history of pregnancy-related hemorrhage
• •Have active gastroduodenal ulcer or other gastrointestinal bleeding diagnosed in the past 3 months
• •Currently are in a hemodynamically unstable state
• •Currently require thrombolysis or pulmonary embolectomy
• •Have history of severe hypersensitivity reaction to Xarelto®
• •Currently have a prosthetic heart valve
• •Have known diagnosis of triple positive antiphospholipid syndrome
• •Have known diagnosis of chronic kidney disease (stage IV or receiving dialysis)
• •Have a history of thrombocytopenia or known platelet count \<100,000 cells/mm\^3
• •Have history of bronchiectasis and pulmonary cavitation
• •Have active cancer (e.g, receiving chemotherapy or treatment for complication of the active cancer)
• •Had epidural or neuraxial anesthesia or spinal puncture in the past 2 weeks and plan to undergo these procedures during the study
• •Had surgery in the past 4 weeks or plan to undergo surgery during the study
• •Currently is pregnant or plans to become pregnant
• •Currently is breastfeeding
• •Share household with an enrolled participant in this study
• •Co-enrollment in any clinical trial that includes prohibited procedures (spinal puncture or surgery) or that includes treatments within the same drug class as rivaroxaban or treatments for which co-administration with rivaroxaban are prohibited. Note that any co-enrollment other than this requires approval by the Sponsor. For any co-enrolled study, the total volume of blood samples collected across the studies should not exceed 275 milliliters (mL) in 4 weeks.
• •Currently using and plan to use the following medications during the study
• •* Rivaroxaban or drugs in the same class
• •* Dual anti-platelets therapy
• •* Other anticoagulants
• •* Combined Permeability glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) inhibitors and inducers